Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.04
--
Market closed
AU$0.04
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.00M
Market Cap
AU$28.38M
Enterprise ValueAU$30.03M
Total Cash (Recent Filing)AU$3.41M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,351,573,000
10 Day Avg. Volume986,343
30 Day Avg. Volume1,997,037
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.74
Price to Sales (P/S)621.50
P/FCF Ratio-28.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA substantial equity base combined with zero reported debt reduces financial leverage and refinancing pressure. This gives Opyl a stronger near-term cushion to fund operations and pursue development initiatives, although the benefit depends on whether the business can eventually convert capital into sustainable returns.
AI Healthcare Business FocusThe company is positioned in a structurally relevant application of AI, using data-driven software to support clinical research and pharmaceutical decisions. If its proprietary platforms gain adoption, this focus could provide scalable opportunities across medical research and drug-development workflows.
Improved Cash BurnThe reduction in cash burn versus 2024 indicates some improvement in cash management or operating performance, providing more time to execute the business plan. This is a modest positive because cash generation remains negative and the company is not yet self-funding.
Bears Say
Persistent Unprofitable OperationsRecurring losses and a deeply negative net margin show that Opyl has not yet established an economically sustainable operating model. Continued unprofitability can consume the equity cushion, restrict reinvestment capacity, and increase dependence on future financing or business improvement.
Severely Reduced Revenue BaseA sharply smaller revenue base limits operating leverage and makes fixed costs difficult to absorb. Persistently low revenue also suggests that product commercialization and customer adoption have not yet reached a scale capable of supporting durable profitability, leaving results vulnerable to volatility.
Ongoing Cash DependenceConsistently negative operating and free cash flow indicates that the business is consuming rather than generating cash. Continued burn may reduce financial flexibility over time and require reliance on reserves or external funding, even though the latest balance sheet reports substantial equity and no debt.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$28.38M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 144 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Aug 31, 2026. The company reported -AU$0.006 earnings per share for the quarter.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 1,351,573,000 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.006 in its last earnings report. Following the earnings report the stock price went down -8.889%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Company Description
Opyl Ltd.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―